Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 4Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 8Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Histiocytoma, Malignant Fibrous 3Urinary Bladder Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Myelodysplastic Syndromes 2Meningioma 2Glioblastoma 2Carcinoma, Transitional Cell 2Carcinoma, Basal Cell 2Vulvar Neoplasms 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Seminoma 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1Rare Diseases 1Pseudomyxoma Peritonei 1Pheochromocytoma 1

Interventions

cabozantinib 2pembrolizumab 1lenvatinib 1fludarabine 1Selenomethionine 1Nivolumab 1Ipilimumab 1Everolimus 1Cyclophosphamide 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Clear-cell metastatic renal cell carcinoma × CTLA-4 Antigen × Clear all
NCT04388852 2026-05-20

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
65 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡